Conflict of interest: none declared.
Ultraviolet A1 phototherapy for mycosis fungoides
Version of Record online: 22 OCT 2012
© The Author(s). CED © 2012 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 38, Issue 2, pages 126–130, March 2013
How to Cite
Olek-Hrab, K., Silny, W., Dańczak-Pazdrowska, A., Osmola-Mańkowska, A., Sadowska, P. A., Polańska, A., Gniadecki, R. and Jenerowicz, D. (2013), Ultraviolet A1 phototherapy for mycosis fungoides. Clinical and Experimental Dermatology, 38: 126–130. doi: 10.1111/ced.12001
- Issue online: 12 FEB 2013
- Version of Record online: 22 OCT 2012
- Accepted for publication 13 June 2012
Background. Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer. UVA1 may be a safer alternative.
Aim. To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1–T2).
Methods. Four patients with early-stage MF were treated with 1630–2710 J/cm2 UVA1 given in 29–40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography.
Results. Complete clinical remission of MF was achieved in all cases.
Conclusions. This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF.